Acute decompensated heart failure

Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release Milrinone Capsule in Late-Stage Heart Failure

Retrieved on: 
Friday, October 8, 2021
Cardiovascular disease, Baker Institute, Center, NYHA, Atrial fibrillation, AHA, Diabetes, Milrinone, Safety, Population, Degenerative disease, Quality of life, Blood pressure, Minnesota, The Alfred Hospital, Company, Intellectual property, Baker Heart and Diabetes Institute, History, IV, HF, Plasma, Cardiology, LinkedIn, FDA, Issuer, CDC, Continuity, Ageing, Disease, Cardiomyopathy, Heart failure, ER, Arrhythmia, Classification, LVAD, Heart, R, PK, Life expectancy, Euronext, Oxygen, Heart rate, Risk, Acute decompensated heart failure, American Heart Association, Journal, Department, New York Heart Association Functional Classification, Blood, Diagnosis, Industry, Digoxin, Heart transplantation, Patient, Muscle tissue, Pharmaceutical industry, Medical device

Milrinone is a positive inotrope, a group of heart failure drugs that strengthen the hearts contractions so it can pump more blood with fewer heartbeats.

Key Points: 
  • Milrinone is a positive inotrope, a group of heart failure drugs that strengthen the hearts contractions so it can pump more blood with fewer heartbeats.
  • Milrinone IV is currently approved for use as an intermittent or continuous infusion for treatment of up to 48 hours for acute decompensated heart failure.
  • The current standard of care is predominantly palliative and despite recent advantages with new heart failure therapies, the effectiveness of these is most pronounced in mild to moderate heart failure.
  • 5 The New York Heart Association (NYHA) Classification provides a way of classifying the extent of heart failure.

Latest Study Shows New Algorithm Can Predict Heart Failure Hospitalizations

Retrieved on: 
Wednesday, August 18, 2021
HF, Acute decompensated heart failure, Defibrillation, Decompensation, Veni, vidi, vici, Time, Heart, Human body, Home Monitoring Aréna, Risk, Patient, SELENE, CRM, Heart failure, Pharmaceutical industry, Hospital, Medical device

Detecting worsening heart failure early and proactively stratifying patients at risk may help improve quality of care and avoid re-hospitalizations.

Key Points: 
  • Detecting worsening heart failure early and proactively stratifying patients at risk may help improve quality of care and avoid re-hospitalizations.
  • "It has the potential to assist the development of an easy-to-use solution that can identify patients at higher risk of worsening heart failure hospitalizations so clinicians can proactively intervene".
  • Combining Home Monitoring temporal trends from implanted defibrillators and baseline patient risk profile to predict heart failure hospitalizations: results from the SELENE HF study.
  • Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures.

Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year

Retrieved on: 
Wednesday, August 4, 2021
Health, Medical Devices, Cardiology, Abiomed, Myocardial infarction, Acute decompensated heart failure, Heart, Patient, Income, Hospital, GAAP, Pulmonary embolism, Annual report, The Final Rule, EPS, DRG, Food and Drug Administration, Medicare, EUA, Decompensation, Security (finance), Technology, Growth, PMA, SEC, Compliance, Food, Nasdaq, Acquisition, Centers for Medicare & Medicaid Services, Research, Stock dilution, U.S. Securities and Exchange Commission, Heart failure, Webcast, COVID-19, Name, Mission statement, Prospective payment system, Form, Hyper-CVAD, CMS, Center, Forecasting, Pharmaceutical industry, Bank

Annually, more than one million patients are admitted to hospitals in the United States with acute decompensated heart failure (ADHF)1.

Key Points: 
  • Annually, more than one million patients are admitted to hospitals in the United States with acute decompensated heart failure (ADHF)1.
  • Despite available pharmaceutical treatments, heart failure is the leading cause of hospitalization in patients older than 65 years of age2.
  • Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation.
  • Impella ECP, Impella XR Sheath, Impella BTR, CVAD, STEMI DTU, Automated Impella Controller and Abiomed Breethe OXY-1 System are pending trademarks of Abiomed, Inc.

Sequana Medical’s results from RED DESERT alfapump DSR® study presented as one of the Highlights at Heart Failure 2021 Online Congress

Retrieved on: 
Tuesday, July 6, 2021
Organ failure, Heart diseases, Branches of biology, Medical specialties, Acute decompensated heart failure, Hypervolemia, Heart failure, Biology

alfapump DSR combines DSR therapy with the proven alfapump to deliver a fully implanted system for long-term DSR therapy.

Key Points: 
  • alfapump DSR combines DSR therapy with the proven alfapump to deliver a fully implanted system for long-term DSR therapy.
  • Strong top-line results from the RED DESERT study showed that repeated dose alfapump DSR therapy in diuretic-resistant heart failure patients is highly effective at managing the fluid and sodium balance and improves cardio-renal status.
  • Sequana Medical has combined its proven alfapump and proprietary DSR therapy, and is developing the alfapump DSR, a breakthrough approach to fluid overload due to heart failure.
  • The SAHARA DESERT study of alfapump DSR in decompensated heart failure patients is ongoing.

Results From Sequana Medical’s RED DESERT alfapump DSR® Study Selected for Presentation at the Heart Failure 2021 Online Congress

Retrieved on: 
Wednesday, June 9, 2021
Heart diseases, Organ failure, Branches of biology, Medical specialties, Hypervolemia, Acute decompensated heart failure, Heart failure, Clinical medicine

The heart failure market for DSR and the alfapump DSR is estimated to be over 5 billion annually in the U.S. and EU5 by 2026.

Key Points: 
  • The heart failure market for DSR and the alfapump DSR is estimated to be over 5 billion annually in the U.S. and EU5 by 2026.
  • DSR is Sequana Medicals proprietary approach to managing sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity.
  • Sequana Medical has combined its proven alfapump and proprietary DSR therapy, and is developing the alfapump DSR, a breakthrough approach to fluid overload due to heart failure.
  • The SAHARA DESERT study of alfapump DSR in decompensated heart failure patients is ongoing.

Results from Sequana Medical’s RED DESERT alfapump DSR® study selected for presentation at the Heart Failure 2021 Online Congress

Retrieved on: 
Wednesday, June 9, 2021
Heart diseases, Organ failure, Branches of biology, Medical specialties, Hypervolemia, Acute decompensated heart failure, Heart failure, Clinical medicine

The heart failure market for DSR and the alfapump DSR is estimated to be over 5 billion annually in the U.S. and EU5 by 2026.

Key Points: 
  • The heart failure market for DSR and the alfapump DSR is estimated to be over 5 billion annually in the U.S. and EU5 by 2026.
  • DSR is Sequana Medicals proprietary approach to managing sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity.
  • Sequana Medical has combined its proven alfapump and proprietary DSR therapy, and is developing the alfapump DSR, a breakthrough approach to fluid overload due to heart failure.
  • The SAHARA DESERT study of alfapump DSR in decompensated heart failure patients is ongoing.

ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure

Retrieved on: 
Monday, May 17, 2021
Anatomy, Branches of biology, Heart diseases, Organ failure, Renal physiology, Ultrafiltration, Acute decompensated heart failure, Heart failure, Kidney

The single-center study evaluated 30 ADHF patients in mainstream setting (i.e., step-down unit, not critical care) who were treated with Aquadex therapy.

Key Points: 
  • The single-center study evaluated 30 ADHF patients in mainstream setting (i.e., step-down unit, not critical care) who were treated with Aquadex therapy.
  • Aquadex achieved gratifying symptom improvement by fluid removal without worsening renal function, and reduced heart failure readmission rates in this cohort of our most challenging patients.
  • \xe2\x80\x9cOur gentle ultrafiltration therapy is built to effectively remove fluid at a customizable rate, which is beneficial for fragile patients such as those with heart failure.
  • Presented at: Heart Failure Society of America Scientific Meeting; Sept. 30-Oct. 6, 2020 (virtual meeting).\nPresident, Chief Executive Officer and Chief Financial Officer, Nuwellis, Inc.\n'

Cardionomic Announces First Patients Enrolled in CPNS Pilot Study

Retrieved on: 
Thursday, April 15, 2021
Branches of biology, Anatomy, Heart diseases, Organ failure, Biology, Neurotechnology, Neuromodulation, Neurophysiology, Neuropsychology, Acute decompensated heart failure, Heart failure

b'MINNEAPOLIS, April 15, 2021 /PRNewswire/ --Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their Cardionomic Pulmonary Neuromodulation System (CPNS) Pilot Study.

Key Points: 
  • b'MINNEAPOLIS, April 15, 2021 /PRNewswire/ --Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their Cardionomic Pulmonary Neuromodulation System (CPNS) Pilot Study.
  • The study will evaluate the safety and performance of the CPNS in patients suffering from Acute Decompensated Heart Failure, defined as new or worsening symptoms of heart failure.
  • The first patients were enrolled by Temistocles Daz, M.D., Principal Investigator at Pacifica Salud Hospital Punta Pacifica in Panama City, Panama.
  • Up to fifty patients are expected to be enrolled worldwide.\nThe Cardionomic Pulmonary Neuromodulation System is founded on the principle that sympathetic nerve stimulation induces cardiac contractility.

WhiteSwell Strengthens Patent Portfolio for Treatment of Acute Decompensated Heart Failure With Newly Issued U.S. Patent

Retrieved on: 
Thursday, December 17, 2020
Health, Medical devices, Cardiology, Anatomy, Branches of biology, Heart diseases, Circulatory system, Organ failure, Acute decompensated heart failure, Heart failure, Congestion, Lymphatic system, Lymph, the Lymphatic System and ADHF, WhiteSwell

WhiteSwell has received 10 patent grants from the U.S. PTO in the last two years, and has a U.S. portfolio of over 40 patents granted or pending.

Key Points: 
  • WhiteSwell has received 10 patent grants from the U.S. PTO in the last two years, and has a U.S. portfolio of over 40 patents granted or pending.
  • WhiteSwell is building a strong intellectual property portfolio and an innovative technology platform to support its pioneering approach: leveraging the power of the lymphatic system to treat congestion in acute decompensated heart failure, said Ronan Keating, WhiteSwells VP of research and development.
  • The lymphatic system, which is vital in removing excess fluid from the bodys tissues, can be overwhelmed during an acute decompensation episode, causing fluid buildup.
  • WhiteSwell is a science-driven company dedicated to improving treatment of acute decompensated heart failure (ADHF), a primary cause of repeat hospitalization and emergency room visits.

CHF Solutions Announces Meta-Analysis Demonstrates Ultrafiltration is Better than Diuretic Therapy for the Management of Volume Overload in ADHF

Retrieved on: 
Tuesday, December 15, 2020
Anatomy, Branches of biology, Heart diseases, Organ failure, Clinical medicine, Acute decompensated heart failure, Ultrafiltration, Hypervolemia, Heart failure, Diuretic, Aquapheresis, Management of heart failure

1

Key Points: 
  • 1
    The article, Ultrafiltration is better than diuretic therapy for volume-overloaded acute heart failure patients: A meta-analysis, included eight randomized controlled studies involving 801 ADHF patients.
  • Data from the analysis demonstrated:
    UF was statistically better than diuretics in terms of increased fluid removal and weight loss.
  • Ultrafiltration is better than diuretic therapy for volume-overloaded acute heart failure patients: a meta-analysis.
  • CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system.